Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
about
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancerPathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms-A whole of population study.Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrenceEpstein criteria for insignificant prostate cancer.Prognostic factors for the development of biochemical recurrence after radical prostatectomy.Rural residency and prostate cancer specific mortality: results from the Victorian Radical Prostatectomy Register.Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy.[Systematic analysis of treatment results as a quality control instrument using the example of a large European center].Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer.Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancersInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?Local recurrence after retropubic radical prostatectomy for prostate cancer does not exclusively occur at the anastomotic site.Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.Health-related quality of life following radical prostatectomy: long-term outcomes.Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence.Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.Q57133489
P2860
Q26774847-20D4D532-80D1-4D5E-A2BD-C8DF6E018D48Q28535425-6F58985B-838F-48BF-84EF-D21EDFC226CFQ34076949-68630AE6-610A-4E98-B966-34CAAD80BA58Q36106227-B3704C6E-68A1-4BDD-8BAA-1225E87A5655Q36954643-4A11334D-5FB7-460F-B89F-3D1C5210E5A5Q37841742-FF779102-62F3-4E45-A292-ADBC827C2395Q37960019-9988739E-D866-4220-9DA7-EE685C339473Q40202813-DD417E82-E146-4984-870D-0F30AA883AC4Q40897976-BA66888C-13BA-4DF9-B618-86B45F48F37BQ41120160-FCF4F507-DF79-4FBD-91E8-594461405F45Q41911247-1A518BC0-ACDD-456C-B837-F346B213A03EQ42567335-507D3F75-A255-48F1-B9B4-7821B9B0E238Q43884608-C344B8B2-E367-4EBB-BA90-8BF84E5E7C8EQ44657084-D10924F4-EEBF-452D-803A-5FE62AFBA78FQ46420605-C38DFEDE-0042-4A75-A605-B177D5DE2E0DQ46990159-07B9D95D-DA8D-4930-92C8-B11322AD73BCQ48083643-A7DD9B11-11AB-4D5C-BC11-7BE27B226A74Q50881669-F8FA4F55-D9BA-4A40-A274-868B3BF07308Q50950330-83832FFB-388D-456B-B789-1B6A70DCBA4EQ52884318-4E3BCD4A-8AEC-4DD4-B07F-D26EED4D8650Q54593106-F98EA314-7E7C-44C6-A297-1BF95F210ED0Q55517777-208B3F48-47B4-40D6-8C0F-774A555932E0Q57133489-D99C9C8D-48BB-4DA7-91F5-780E200BF017
P2860
Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Long-term data on the survival ...... prostate-specific antigen era.
@ast
Long-term data on the survival ...... prostate-specific antigen era.
@en
Long-term data on the survival ...... prostate-specific antigen era.
@nl
type
label
Long-term data on the survival ...... prostate-specific antigen era.
@ast
Long-term data on the survival ...... prostate-specific antigen era.
@en
Long-term data on the survival ...... prostate-specific antigen era.
@nl
prefLabel
Long-term data on the survival ...... prostate-specific antigen era.
@ast
Long-term data on the survival ...... prostate-specific antigen era.
@en
Long-term data on the survival ...... prostate-specific antigen era.
@nl
P2093
P1433
P1476
Long-term data on the survival ...... prostate-specific antigen era.
@en
P2093
Alexander Haese
Georg Salomon
Guido Sauter
Hans Heinzer
Hartwig Huland
Hendrik Isbarn
Jens Köllermann
Manuela Wanner
Markus Graefen
Thomas Steuber
P356
10.1111/J.1464-410X.2009.09134.X
P577
2009-12-11T00:00:00Z